Wednesday 27th January, 2021
PAWs Beginner workshop
Coordinator: Dr Hesham Al-Sallami
| 0830 – 0930 AEDT | Introduction to population methods |
| 1000 – 1100 AEDT | NONMEM demonstration |
| 1130 – 1230 AEDT | Building structural and covariate models |
PAWs Intermediate workshop
Coordinator: Professor Nick Holford
| 0830 – 0930 AEDT | Introduction to time to event analysis |
| 1000 – 1100 AEDT | Demonstration |
| 1100 – 1130 AEDT | Q&A Session |
Thursday 28th January, 2021
| 0900 – 0905 AEDT | Dr Sophie Stocker | Welcome |
| ISoP Lectureship | ||
| 0905 – 1005 AEDT | Prof Rada Savic | Reinventing Clinical Trial Designs for TB Regimen Development |
| Oral Presentation Session 1 Chair: Dr Stephanie Reuter Lange | ||
| 1015 – 1030 AEDT | Ranita Kirubakaran | Matters close to the heart: adaptation of tacrolimus models to inform therapeutic drug monitoring using the PRIOR approach |
| 1030 – 1045 AEDT | Dr Jeffrey Adiwidjaja | Implementation of a physiologically-based pharmacokinetic modelling approach to evaluate inter-ethnic differences in imatinib dosing regimens |
| 1045 – 1100 AEDT | Dr Hannah Kim | Saliva Population PK Model for Voriconazole |
| 1100 – 1115 AEDT | Dr Michael Dolton | PBPK Modeling of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-dependent Solubility and Nonsink Permeation |
| Oral Presentation Session 2 Chair: Dr Derek Zhu | ||
| 1600 – 1615 AEDT | Pieter Van Brantegem | A model-based evaluation of the effect of bosentan on bile salt disposition in sandwich-cultured human hepatocytes |
| 1615 – 1630 AEDT | Zhigang Wang | Modeling of The Relationship Between Ustekinumab Exposure, Fecal Calprotectin and Endoscopic Outcomes in Patients with Crohn’s Disease |
| 1630 – 1645 AEDT | Omar Elkayal | Population pharmacokinetics of cefazolin in maternal and umbilical cord sera and target attainment in term neonates |
| 1645 – 1700 AEDT | David W. Uster | Improved predictive performance using a model averaging algorithm in model-informed precision dosing of vancomycin |
| PAGANZ Trivia | ||
| 1730 – 1830 AEDT | Trivia hosted by | Ranita Kirubakaran, Guangda Ma, Amelia Cossart |
Friday 29th January, 2021
| 0900 – 1000 AEDT | PAGANZ Annual General Meeting Chair: Associate Professor David Foster | |
| Oral Presentation Session 3 Chair: Dr Ahmad Abuhelwa | ||
| 1000 – 1015 AEDT | Jingyun Li | A quantitative systems pharmacology model for paracetamol overdose and rescue |
| 1015 – 1030 AEDT | Suchaya Sanhajariya | Investigating myotoxicity following red-bellied black snake envenomation |
| 1030 – 1045 AEDT | Sepi Sharif | Exploring and optimising the computational efficiency of Inductive Linearisation for estimation |
| 1045 – 1100 AEDT | Rachael Lawson | A population pharmacokinetic model of once daily intravenous busulfan in paediatrics characterising time-dependent clearance |
| Poster Presentation Session Chair: Shaun Kumar | ||
| 1200 – 1205 AEDT | Sima Sadrai | Population Pharmacokinetics Modeling of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI) |
| 1205 – 1210 AEDT | Sudeep Pradhan | Evaluation of the intact nephron hypothesis using optimal design methodology |
| 1210 – 1215 AEDT | Shengjie Zhang | Pharmacokinetic modelling for remdesivir |
| 1215 – 1220 AEDT | James D Morse | A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults |
| 1220 – 1225 AEDT | Abdallah Derbalah | QSP Model Simplification Using Machine Learning with an Application to Heparin Dose-Response in Children |
| 1225 – 1230 AEDT | Rachael Hickey | Toward an in silico viral kinetic model for Covid-19 with pharmacodynamic effects |
| 1230 – 1235 AEDT | Jian Lynn Lee | Impact of genetic and non-genetic factors on the pharmacokinetics of intravenous immunoglobulin in patients with predominantly antibody deficiencies in Malaysia |
| 1235 – 1240 AEDT | Mohamed Tarek | Analysis of Laplace Approximation for Pharmaceutical Nonlinear Mixed Effects Models |
| 1240 – 1245 AEDT | Akosua A. Agyeman | Mechanism-based modelling of meropenem plus tobramycin combination regimens against clinical hypermutable Pseudomonas aeruginosa in the hollow-fibre infection model |
| 1245 – 1250 AEDT | Guangda Ma | External Evaluation of Vancomycin Models |
| 1250 – 1255 AEDT | Estelle Yau | Physiologically-based pharmacokinetic (PBPK) models for translation of drug distribution from rat to human |
| 1255 – 1300 AEDT | Liang Yang | A mathematical model of CB1 receptor allosteric modulation |
| 1300 – 1305 AEDT | Conor O’Hanlon | An ex vivo study measuring antibiotic adsorption to cardiopulmonary bypass circuitry |
| 1305 – 1310 AEDT | Pieter Van Brantegem | A population pharmacokinetic model of sildenafil in an extra-uterine system for premature lambs |
| 1310– 1315 AEDT | Laurynas Mockeliunas | A Population Pharmacokinetic Model of Linezolid enabling Model-Informed Precision Dosing in Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis |
| 1315– 1320 AEDT | Dala N Daraghmeh | Association between seropositivity and remission in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs: a retrospective analysis of 5 phase III randomized clinical trials of tocilizumab |
| 1320– 1325 AEDT | Sebastian Rosse | Population pharmacokinetics of dimethylacetamide in children receiving intravenous busulphan |
| 1325– 1330 AEDT | Alejandra Schiavo | Prediction of multiple-dose relative bioavailability outcome for an extended release valproic acid formulation |
| 1330– 1335 AEDT | Valentina Topić Vučenović | The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach |
| Oral Presentation Session 4 Chair: Dr Katrina Hiu | ||
| 1600 – 1615 AEDT | Dr Jacqueline A Hannam | A model for procalcitonin concentrations following birth in non infected preterm neonates |
| 1615 – 1630 AEDT | Dr Xiao Zhu | Determination of the pharmacodynamics of vancomycin in young infants via time-to-event analysis |
| 1630 – 1645 AEDT | Professor Stephen Duffull | Issues with virtual populations when applied to nonlinear QSP models |
| 1645 – 1700 AEDT | Harvey Ho | Extrapolating pharmacokinetic models from adults to neonates and infants: Case studies with paracetamol |
| SARS-CoV-2 Session | ||
| 1700-1730 AEDT | Antonio Goncalves | Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load |
| 1730-1800 AEDT | Dr Michael Dodds | Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19 |
| 1800 – 1815 AEDT | Dr Sophie Stocker | Meeting closes |